one8zero8 LLC Takes $499,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

one8zero8 LLC purchased a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,700 shares of the biotechnology company's stock, valued at approximately $499,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Rocket Pharmaceuticals by 22.8% during the 3rd quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company's stock worth $207,642,000 after purchasing an additional 2,086,424 shares in the last quarter. Westfield Capital Management Co. LP grew its position in shares of Rocket Pharmaceuticals by 3.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company's stock worth $83,001,000 after purchasing an additional 165,911 shares in the last quarter. Maverick Capital Ltd. grew its position in shares of Rocket Pharmaceuticals by 4.8% during the 3rd quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company's stock worth $76,072,000 after purchasing an additional 190,360 shares in the last quarter. State Street Corp grew its position in shares of Rocket Pharmaceuticals by 11.6% during the 3rd quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company's stock worth $57,294,000 after purchasing an additional 322,156 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Rocket Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,617,866 shares of the biotechnology company's stock worth $29,888,000 after purchasing an additional 14,256 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

RCKT has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $29.00 target price on the stock. Canaccord Genuity Group decreased their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Chardan Capital decreased their target price on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Needham & Company LLC reduced their price target on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Finally, Wedbush began coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an "outperform" rating and a $32.00 price target on the stock. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Rocket Pharmaceuticals Price Performance

NASDAQ:RCKT traded down $0.14 on Thursday, hitting $8.32. The company had a trading volume of 1,181,871 shares, compared to its average volume of 991,074. The stock has a market capitalization of $887.16 million, a price-to-earnings ratio of -3.03 and a beta of 1.03. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $10.00 and a two-hundred day moving average of $13.76. Rocket Pharmaceuticals, Inc. has a 52 week low of $8.06 and a 52 week high of $28.67.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06. On average, research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.